How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Cardiogenic Shock Market
- By Etiology: Acute Myocardial Infarction, Acute Decompensated Heart Failure, Myocarditis, Valvular Heart Disease, Arrhythmias
- By Treatment Modality: Pharmacological Therapy, Mechanical Circulatory Support, Revascularization Procedures, Heart Transplantation, Extracorporeal Membrane Oxygenation (ECMO)
- By Mechanical Circulatory Support Device Type: Intra-Aortic Balloon Pump (IABP), Impella Device, Ventricular Assist Devices (VADs), Extracorporeal Membrane Oxygenation (ECMO), TandemHeart
- By Patient Age Group: Pediatric, Adult, Geriatric
- By Clinical Setting: Intensive Care Unit (ICU), Cardiac Care Unit (CCU), Emergency Department
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Acute Myocardial Infarction leads By Etiology at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 296 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.180 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.188 →
Full report · locked preview
Everything inside the Cardiogenic Shock Market report
A complete, evidence-based study - 12 chapters and 124 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Etiology 5
Treatment Modality 5
Mechanical Circulatory Support Device Type 5
Patient Age Group 3
Clinical Setting 3
Companies profiled
Abbott Laboratories
Medtronic plc
Abiomed Inc.
Getinge AB
Terumo Corporation
Edwards Lifesciences Corporation
Boston Scientific Corporation
Stryker Corporation
Philips Healthcare
CardiacAssist Inc.
LivaNova PLC
Maquet Getinge Group
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Abbott Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Medtronic plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Abiomed Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Getinge AB
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Terumo Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Edwards Lifesciences Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Boston Scientific Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Stryker Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Philips Healthcare
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →CardiacAssist Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →LivaNova PLC
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Maquet Getinge Group
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Zoll Medical Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Nipro Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →B. Braun Melsungen AG
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$1,586M by 2033 · 8.8% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Acute Myocardial Infarction51.0
- Acute Decompensated Heart Failure12.7
- Myocarditis9.1
- Valvular Heart Disease15.8
- Arrhythmias11.4
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$266.0M → $584.0M · 10.3%
Europe$185.4M → $347.3M · 8.2%
Asia Pacific$169.3M → $364.2M · 10.1%
Latin America$104.8M → $184.0M · 7.3%
Middle East and Africa$80.6M → $170.7M · 9.8%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →8.782026
8.792027
8.802028
8.822029
8.822030
8.842031
8.862032
8.872033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Abbott Laboratories20.3
- Medtronic plc15.0
- Abiomed Inc.10.9
- Getinge AB7.9
- Terumo Corporation9.0
- Edwards Lifesciences Corporation8.9
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Etiology13.4%
Treatment Modality23.7%
Mechanical Circulatory Support Device Type18.1%
Patient Age Group18.0%
Clinical Setting26.9%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America35.4
- Europe21.0
- Asia Pacific22.1
- Latin America11.2
- Middle East and Africa10.3
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | 89 | 96 | 76 | 99 | 98 | 77 | 89 |
| Medtronic plc | 70 | 74 | 82 | 89 | 75 | 83 | 79 |
| Abiomed Inc. | 70 | 76 | 84 | 65 | 82 | 76 | 76 |
| Getinge AB | 59 | 69 | 66 | 75 | 58 | 78 | 68 |
| Terumo Corporation | 63 | 65 | 72 | 51 | 59 | 53 | 61 |
| Edwards Lifesciences Corporation | 65 | 48 | 71 | 71 | 48 | 57 | 60 |
| Boston Scientific Corporation | 45 | 52 | 41 | 64 | 41 | 41 | 47 |
| Stryker Corporation | 54 | 35 | 44 | 44 | 37 | 42 | 43 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Abbott Laboratories
- Medtronic plc
- Abiomed Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Abbott Laboratories | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Medtronic plc | ✓ | ◐ | ✓ | ✓ | ◐ | ✓ |
| Abiomed Inc. | ◐ | ◐ | ◐ | ◐ | ✓ | ✓ |
| Getinge AB | − | ◐ | ◐ | ◐ | ◐ | ◐ |
| Terumo Corporation | ✓ | ✓ | − | − | − | ◐ |
| Edwards Lifesciences Corporation | ◐ | − | ◐ | ◐ | − | ◐ |
| Boston Scientific Corporation | − | − | − | ◐ | ◐ | − |
| Stryker Corporation | ◐ | − | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Abbott Laboratories89
2Medtronic plc79
3Abiomed Inc.76
4Getinge AB68
5Terumo Corporation61
6Edwards Lifesciences Corporation60
7Boston Scientific Corporation47
8Stryker Corporation43
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Abbott LaboratoriesMedtronic plc
Challenger2
Strong scale, closing on the leaders.
Abiomed Inc.Getinge AB
Contender2
Focused players with pockets of strength.
Terumo CorporationEdwards Lifesciences Corporation
Niche2
Specialists in a single segment or region.
Boston Scientific CorporationStryker Corporation
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Etiology in North America, then scale across Cardiogenic Shock Market — a $487M beachhead inside a $8.82B market.
Beachhead (SOM)$487Mobtainable near-term
Serviceable (SAM)$3.27Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Acute Myocardial Infarction
Best fit — highest urgency & budget in Etiology.
Economic buyer77 fit
Acute Decompensated Heart Failure
Strong fit — clear ROI and a fast path to value.
End user67 fit
Myocarditis
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Etiology in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Treatment Modality & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Mechanical Circulatory Support Device Type
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel27%
Digital / self-serve22%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Etiology leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Cardiogenic Shock Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified40%
Sales qualified21%
Evaluation14%
Closed-won7%
$14.1KCAC
$57KLTV
4.0:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Cardiogenic Shock Market is a high-growth opportunity — $9.70B by 2033, compounding at 10.1%.
TAM · 2025$4.48Btoday
TAM · 2033$9.70Bforecast
CAGR10.1%2027–2033
Cumulative$61.2Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$9.70BTotal addressable market
SAM$4.04BServiceable available market
SOM$885MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.1% CAGR
Demand compounds through 2033, outpacing GDP across Etiology.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Etiology moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$9.70BLarge & growingTAM by 2033 at 10.1% CAGR
$4.04BServiceable nowreachable with today’s model
$885MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$7.57BBear6.6% CAGR
$9.70BBase10.1% CAGR
$12.4BBull13.4% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Treatment Modality optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Cardiogenic Shock Market — a $1.62B market by 2033. Plan: grow share from 5.7% to 11.4%.
Market size · 2033$1.62Btotal addressable
Market CAGR7.0%2027–2033
Target share11.4%from 5.7% today
Revenue ambition$184Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 5.7% | 11.4% | Behind |
| Revenue | $89M | $184M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 37.9% | 42.2% | On track |
| Customer retention | 88.3% | 92.2% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Etiology
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Treatment Modality capability
A defensible second engine — invest in Treatment Modality to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Etiology share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Treatment Modality
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $25M capacity & capability investment
- Greenlight bolt-on M&A in Treatment Modality
- Authorise North America expansion plan
- Fund R&D program for Etiology leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossAt risk
- Input-cost & supply riskAt risk
- Regulatory / policy changeAt risk
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Cardiogenic Shock Market conversation — a $3.54B market you can size, segment and defend in minutes.
Market size · 2033$3.54Btotal opportunity
Growth7.6%CAGR to 2033
Addressable buyers1,395+accounts in scope
Typical ROI7.3×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Etiology
Goal Grow share in Etiology
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.3×return on cost, year one
< 2 mopayback period
$68K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Abbott LaboratoriesMedtronic plcAbiomed Inc.Getinge ABTerumo CorporationEdwards Lifesciences CorporationBoston Scientific CorporationStryker Corporation+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Cardiogenic Shock Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Cardiogenic Shock Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Cardiology Market
Market size, share, segmentation and regional forecast.
$596M market · 2025 base year
View reportCardiometabolic Disease Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportCardiometabolic Monitoring Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportCardiopulmonary Emergency Cart Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportCardio-Pulmonary Resuscitation Barrier Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportCardiopulmonary Resuscitation Simulator Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportCardiothoracic Use Sealant Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportCardiovascular Application Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportCardiovascular Balloon Catheters Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportCardiovascular Catheter Guidewires Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportCardiovascular Diagnostic Device Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportCardiovascular Molecular Imaging Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.